|
|
Background: The current study aims to investigate the clinical significance of serum macrophage migration inhib-itory factor (MIF) and C-C motif chemokine living 23 (CCL23) in patients with acute cerebral infarction (ACI).
Methods: Seventy-nine patients with ACI were selected and divided into three types, including large-area atherosclerosis (LAA), cardiovascular central embolism (CCE), and small-area occlusion (SAO) according to the Trial of Org 10172 in Acute Stroke Treatment or TOAST. At the same time, 79 healthy people were selected as the control group. The concentrations of MIF and CCL23 were measured by ELISA. Pearson’s correlation assay was carried out to explore the correlation between MIF, CCL23, and clinical index. The diagnostic value of MIF and CCL23 was evaluated using ROC analysis.
Results: Our data showed that both of MIF and CCL23 levels were significantly enhanced in the serum of ACI patients compared to controls. Pearson’s correlation assay indicated that serum MIF and CCL23 levels were positively correlated with NIHSS score, but negatively correlated with Barthel index. Moreover, the concentrations of MIF and CCL23 in CCE and LAA subgroups were significantly higher than those in SAO subgroups, while there was no statistical significance between CCE and LAA subgroups. ROC curve showed that combined use of MIF and CCL-23 demonstrated a better AUC of 0.903 (95% CI: 0.840 - 0.966), with the sensitivity and specificity of 0.91 and 0.87, respectively.
Conclusions: In summary, both MIF and CCL23 were significantly increased in ACI patients. Combined use of MIF and CCL23 may be helpful in the diagnosis of ACI.
DOI: 10.7754/Clin.Lab.2020.200239
|
